Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

Deborah A. Kuban, Lawrence B. Levy, M. Rex Cheung, Andrew K. Lee, Seungtaek Choi, Steven Frank, Alan Pollack

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Purpose: To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer. Materials and Methods: A total of 301 patients with Stage T1b-T3 prostate cancer treated to 70 Gy versus 78 Gy now have a median follow-up of 9 years. Failure patterns and survival were compared between dose levels. The cumulative incidence of death from prostate cancer versus other causes was examined and regression analysis was used to establish predictive factors. Results: Patients with pretreatment prostate-specific antigen (PSA) >10 ng/mL or high-risk disease had higher biochemical and clinical failures rates when treated to 70 Gy. These patients also had a significantly higher risk of dying of prostate cancer. Patients <70 years old at treatment died of prostate cancer nearly three times more frequently than of other causes when they were radiated to 70 Gy, whereas those treated to 78 Gy died of other causes more frequently. Patients age 70 or older treated to 70 Gy died of prostate cancer as often as other causes, and those receiving 78 Gy never died of prostate cancer within 10 years of follow-up. In regression analysis, factors predicting for death from prostate cancer were pretreatment PSA >10.5 ng/mL, Gleason score 9 and 10, recurrence within 2.6 years of radiation, and doubling time of <3.6 months at the time of recurrence. Conclusions: Moderate dose escalation (78 Gy) decreases biochemical and clinical failure as well as prostate cancer death in patients with pretreatment PSA >10 ng/mL or high-risk disease.

Original languageEnglish
Pages (from-to)1310-1317
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume79
Issue number5
DOIs
StatePublished - Apr 1 2011

Fingerprint

Prostatic Neoplasms
cancer
dosage
Survival
Neoplasm Grading
antigens
Prostate-Specific Antigen
death
pretreatment
regression analysis
radiation therapy
Radiotherapy
incidence
Regression Analysis
Radiation
Recurrence
causes
Incidence
radiation

Keywords

  • Dose escalation
  • Failure patterns
  • Prostate cancer
  • Radiotherapy
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? / Kuban, Deborah A.; Levy, Lawrence B.; Cheung, M. Rex; Lee, Andrew K.; Choi, Seungtaek; Frank, Steven; Pollack, Alan.

In: International Journal of Radiation Oncology Biology Physics, Vol. 79, No. 5, 01.04.2011, p. 1310-1317.

Research output: Contribution to journalArticle

Kuban, Deborah A. ; Levy, Lawrence B. ; Cheung, M. Rex ; Lee, Andrew K. ; Choi, Seungtaek ; Frank, Steven ; Pollack, Alan. / Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 79, No. 5. pp. 1310-1317.
@article{380b40f6ba764366b986f8d34abf46a5,
title = "Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?",
abstract = "Purpose: To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer. Materials and Methods: A total of 301 patients with Stage T1b-T3 prostate cancer treated to 70 Gy versus 78 Gy now have a median follow-up of 9 years. Failure patterns and survival were compared between dose levels. The cumulative incidence of death from prostate cancer versus other causes was examined and regression analysis was used to establish predictive factors. Results: Patients with pretreatment prostate-specific antigen (PSA) >10 ng/mL or high-risk disease had higher biochemical and clinical failures rates when treated to 70 Gy. These patients also had a significantly higher risk of dying of prostate cancer. Patients <70 years old at treatment died of prostate cancer nearly three times more frequently than of other causes when they were radiated to 70 Gy, whereas those treated to 78 Gy died of other causes more frequently. Patients age 70 or older treated to 70 Gy died of prostate cancer as often as other causes, and those receiving 78 Gy never died of prostate cancer within 10 years of follow-up. In regression analysis, factors predicting for death from prostate cancer were pretreatment PSA >10.5 ng/mL, Gleason score 9 and 10, recurrence within 2.6 years of radiation, and doubling time of <3.6 months at the time of recurrence. Conclusions: Moderate dose escalation (78 Gy) decreases biochemical and clinical failure as well as prostate cancer death in patients with pretreatment PSA >10 ng/mL or high-risk disease.",
keywords = "Dose escalation, Failure patterns, Prostate cancer, Radiotherapy, Survival",
author = "Kuban, {Deborah A.} and Levy, {Lawrence B.} and Cheung, {M. Rex} and Lee, {Andrew K.} and Seungtaek Choi and Steven Frank and Alan Pollack",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2010.01.006",
language = "English",
volume = "79",
pages = "1310--1317",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

AU - Kuban, Deborah A.

AU - Levy, Lawrence B.

AU - Cheung, M. Rex

AU - Lee, Andrew K.

AU - Choi, Seungtaek

AU - Frank, Steven

AU - Pollack, Alan

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose: To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer. Materials and Methods: A total of 301 patients with Stage T1b-T3 prostate cancer treated to 70 Gy versus 78 Gy now have a median follow-up of 9 years. Failure patterns and survival were compared between dose levels. The cumulative incidence of death from prostate cancer versus other causes was examined and regression analysis was used to establish predictive factors. Results: Patients with pretreatment prostate-specific antigen (PSA) >10 ng/mL or high-risk disease had higher biochemical and clinical failures rates when treated to 70 Gy. These patients also had a significantly higher risk of dying of prostate cancer. Patients <70 years old at treatment died of prostate cancer nearly three times more frequently than of other causes when they were radiated to 70 Gy, whereas those treated to 78 Gy died of other causes more frequently. Patients age 70 or older treated to 70 Gy died of prostate cancer as often as other causes, and those receiving 78 Gy never died of prostate cancer within 10 years of follow-up. In regression analysis, factors predicting for death from prostate cancer were pretreatment PSA >10.5 ng/mL, Gleason score 9 and 10, recurrence within 2.6 years of radiation, and doubling time of <3.6 months at the time of recurrence. Conclusions: Moderate dose escalation (78 Gy) decreases biochemical and clinical failure as well as prostate cancer death in patients with pretreatment PSA >10 ng/mL or high-risk disease.

AB - Purpose: To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer. Materials and Methods: A total of 301 patients with Stage T1b-T3 prostate cancer treated to 70 Gy versus 78 Gy now have a median follow-up of 9 years. Failure patterns and survival were compared between dose levels. The cumulative incidence of death from prostate cancer versus other causes was examined and regression analysis was used to establish predictive factors. Results: Patients with pretreatment prostate-specific antigen (PSA) >10 ng/mL or high-risk disease had higher biochemical and clinical failures rates when treated to 70 Gy. These patients also had a significantly higher risk of dying of prostate cancer. Patients <70 years old at treatment died of prostate cancer nearly three times more frequently than of other causes when they were radiated to 70 Gy, whereas those treated to 78 Gy died of other causes more frequently. Patients age 70 or older treated to 70 Gy died of prostate cancer as often as other causes, and those receiving 78 Gy never died of prostate cancer within 10 years of follow-up. In regression analysis, factors predicting for death from prostate cancer were pretreatment PSA >10.5 ng/mL, Gleason score 9 and 10, recurrence within 2.6 years of radiation, and doubling time of <3.6 months at the time of recurrence. Conclusions: Moderate dose escalation (78 Gy) decreases biochemical and clinical failure as well as prostate cancer death in patients with pretreatment PSA >10 ng/mL or high-risk disease.

KW - Dose escalation

KW - Failure patterns

KW - Prostate cancer

KW - Radiotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=79952701542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952701542&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.01.006

DO - 10.1016/j.ijrobp.2010.01.006

M3 - Article

C2 - 20493642

AN - SCOPUS:79952701542

VL - 79

SP - 1310

EP - 1317

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -